Navigation Links
JAZZ PHARMACEUTICALS ANNOUNCES FIRST QUARTER 2013 FINANCIAL RESULTS
Date:5/7/2013

this press release.

In May 2013, our board of directors authorized the use of up to $200 million to repurchase the company's ordinary shares. The timing and amount of repurchases will depend on a variety of factors, including the price of the company's ordinary shares, alternative investment opportunities, restrictions under our existing credit agreement, corporate and regulatory requirements and market conditions. 

First Quarter 2013 Revenues and Product SalesTotal revenues for the first quarter of 2013 were $196.2 million, compared to total revenues of $102.5 million for the first quarter of 2012. The increase in total revenues for the quarter ended March 31, 2013 was driven primarily by inclusion of revenues from the acquired EUSA Pharma business and increased net sales of Xyrem® (sodium oxybate) oral solution.

Total revenues for the quarter ended March 31, 2013 included net sales, royalties and contract revenues. A table showing net sales for the first quarter of 2013 compared to pro forma net sales for the first quarter of 2012 is included in this press release.

Net sales for the first quarter of 2013 were as follows:

  • Xyrem®:  First quarter 2013 Xyrem sales increased by 60% to $117.5 million compared to $73.4 million during the first quarter of 2012.  During the first quarter of 2013, the average number of active Xyrem patients was approximately 10,550.
  • Erwinaze®/Erwinase® (asparaginase Erwinia chrysanthemi):  First quarter 2013 worldwide net sales of Erwinaze/Erwinase were $41.8 million compared to first quarter 2012 pro forma net sales of $32.9 million. 
  • Prialt® (ziconotide) intrathecal infusion:  First quarter 2013 net sales of Prialt were $5.0 million compared to pro forma net sales of $9.9 million in the same period of 2012.  The higher pro forma net s
    '/>"/>

  • SOURCE Jazz Pharmaceuticals plc
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14

    Related medicine technology :

    1. Isis Pharmaceuticals Announces Proposed Public Offering of Common Stock
    2. Alexza Pharmaceuticals to Present at Antiepileptic Drug and Device Trials (AED) XII Conference Highlighting Advances in the Treatment of Epilepsy
    3. Kinex Pharmaceuticals and Zenith Technology Corporation announce the execution of a collaborative licensing agreement
    4. Isis Pharmaceuticals Announces the Initiation of a Clinical Study of ISIS-STAT3 Rx in Patients with Liver Cancer
    5. AcelRx Pharmaceuticals to Hold First Quarter 2013 Financial Results Conference Call and Webcast on May 8, 2013
    6. Valeant Pharmaceuticals Provides Efinconazole Update
    7. Arena Pharmaceuticals Provides Corporate Update and Reports First Quarter 2013 Financial Results
    8. Cumberland Pharmaceuticals Reports First Quarter Financial Results
    9. OncoGenex Pharmaceuticals, Inc. Provides Clinical Development Program Overview and Reports Financial Results for First Quarter 2013
    10. Webcast Alert: Isis Pharmaceuticals First Quarter 2013 Financial Results Conference Call
    11. Optimer Pharmaceuticals to Host Conference Call and Webcast to Discuss First Quarter 2013 Financial Results
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:1/15/2014)... , Jan. 15, 2014  Humberto C. Antunes,  Galderma  worldwide ... from the Journal of Drugs in Dermatology ... Conference (ODAC). The event is January 17-20, 2014, at the Omni ... . The ODAC is a distinguished ...
    (Date:1/15/2014)... , Jan. 15, 2014 Tegra Medical is very pleased ... as its new Chief Executive Officer.  Mark was promoted ... he has overseen the company,s four facilities in ... Rica.  Mr. King joined Tegra Medical in 2012 with 20+ ...
    (Date:1/15/2014)... 2014  According to Millennium Research Group (MRG), the ... the United States and European ... expand moderately through 2022, with embolization particles representing ... interest in drug-eluting beads (DEBs) and radioembolization spheres ...
    Breaking Medicine Technology:Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 2Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 3Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 4Tegra Medical Appoints New Chief Executive Officer 2Tegra Medical Appoints New Chief Executive Officer 3US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 2US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 3
    ... 2011 , ReportsnReports adds market ... & Forecasts to 2017 for Greece, Hungary & ... provide value (USD million), volume (units) and average ... within 10 market categories - Cardiac Assist Devices, ...
    ... Mass., Sept. 20, 2011 Intrinsic Therapeutics, a ... address the spine market,s many unmet needs, today ... and Chief Executive Officer. Mr. Hagan brings over ... field with significant expertise in product development, commercialization ...
    Cached Medicine Technology:ReportsnReports - Cardiovascular Devices Investment Opportunities, Analysis & 2017 Forecasts: Greece, Hungary, Ireland 2ReportsnReports - Cardiovascular Devices Investment Opportunities, Analysis & 2017 Forecasts: Greece, Hungary, Ireland 3ReportsnReports - Cardiovascular Devices Investment Opportunities, Analysis & 2017 Forecasts: Greece, Hungary, Ireland 4Intrinsic Therapeutics, Inc. Names Cary P. Hagan as President & CEO 2
    (Date:7/10/2014)... health-conscious people around the globe have taken antioxidant supplements ... one of the paths to good health and a ... antioxidant supplements have repeatedly dashed the hopes of consumers ... Virtually all such trials have failed to show ... several trials antioxidant supplementation has been linked with increased ...
    (Date:7/10/2014)... Manchester scientists have shown that a new drug could prove ... aggressive form of lung cancer. , Scientists from the Cancer ... and part of the Manchester Cancer Research Centre, teamed up ... in 2010, to test a drug known as AZD3965 ... published in the journal Clinical Cancer Research , also ...
    (Date:7/9/2014)... reveal that sudden, acute episodes of low back pain ... humidity, air pressure, wind direction and precipitation. Findings published ... of the American College of Rheumatology (ACR), indicate that ... higher wind speed or wind gusts, but was not ... Organization (WHO) nearly everyone experiences low back pain at ...
    (Date:7/9/2014)... CHICAGO After Susan Wakulich was told she had an ... lay ahead of her. , "I was devastated," said Wakulich, ... suburbs. "I knew this was a serious diagnosis. Then I ... trial that involved a less invasive procedure. It was something ... is participating in a multi-center U.S. clinical trial to evaluate ...
    (Date:7/9/2014)... into the metabolism of stromal support cells and immune ... these cell types in the development of diseases ... and cancer. That was the conclusion of a review ... the leading journal Nature . , Prof. Peter ... call. The metabolism of cancer cells has been examined ...
    Breaking Medicine News(10 mins):Health News:How antioxidants can accelerate cancers, and why they don't protect against them 2Health News:New drug active against most aggressive type of lung cancer cells 2Health News:Low back pain? Don't blame the weather 2Health News:New type of stent could help some brain aneurysm patients 2Health News:Wake-up call for more research into cell metabolism 2
    ... price of efavirenz 600mg tablets (Stocrin) for developing countries that ... ,It is the second price cut in a ... efavirenz cheaper than a generic import in Thailand, where a ... from India. ,For least developed countries and ...
    ... case management that takes a patient’s specific culture ... decrease the incidence of diabetes-related complications over the ... ,"Better management results in reduced long-term complications, such ... lead researcher Todd Gilmer, Ph.D. ,The ...
    ... Japanese researchers have successfully developed artificial teeth that they ... eventually help with similar procedures in humans. ... a single cell implanted into the mouths of adult ... in humans, reported the online edition of Australia's The ...
    ... Insufficient sleep at night could have an adverse effect ... that shows// how important the evening slumber is for ... University Of Colorado School Of Medicine and other researchers ... out by students attending middle school or high school, ...
    ... not worry about getting their bodies back into shape immediately, ... body has enough to do after a baby arrives," said ... ,New mothers also have to reckon with fatigue ... Pfarrer of the insurer DAK in Hamburg. And nursing a ...
    ... have literally found the needle in the haystack as ... help to discover hitherto unknown genetic material that causes ... in the prevention and treatment of autism has been ... all part of an international team from 8 countries ...
    Cached Medicine News:Health News:Culturally Specific Diabetes Management Helps Low-Income Patients 2Health News:Sleep Disturbances Could Affect Performances in School 2Health News:New Gene Linked to Autism Discovered 2
    Lyphochek Assayed Chemistry Control requires no special diluent and has good reconstituted stability for enzymes and CO2. It is assayed for most major instruments and methodologies....
    Liquichek Therapeutic Drug Monitoring Control (TDM) is a liquid assayed control containing a comprehensive menu of therapeutic drugs, as well as many common ligands. Available in three levels....
    Lyphochek Urine Metals Control incorporates two levels of critical trace elements, heavy metals and organic metabolites, and is ideal for environmental and industrial testing....
    Liquichek Urine Chemistry Control is a liquid product ideal for monitoring urine chemistry testing procedures. It provides assayed values for urine tests commonly performed on chemistry analyzers and...
    Medicine Products: